Abstract: Double-stranded DNA molecules characterised in that they are circular and in that they essentially include one or more genes of interest.

Abstract: Devices, processes and compositions are provided for effective separation of cells from a mixture of cells, where depletion or positive selection may be employed to provide a cellular population of interest. Of particular utility is the separation of cells from peripheral blood mononuclear cells, where members of the lymphoid or myeloid lineages may be isolated and used for research, diagnosis or therapy. Also of interest are cellular separation from bone marrow, tumor suspensions or lymphoid tissue suspensions, where cells can be isolated and used for a variety of purposes. The separated cells may be homogeneous, free of exogenous biologicals, viable, capable of replication and exhibit their full complement of biological activities. Multiple phenotypes can be captured simultaneously. Captured cells can be specifically activated with cytokines and antigens to provide cells which are MHC restricted and have antigen-specific effector functions.

Abstract: The present invention pertains to the use of compounds affecting the activity of transcription factors for the preparation of a pharmaceutical composition for the treatment of neurodegenerative diseases.

Abstract: The invention relates to cells usable for the production of defective adenoviruses comprising, inserted into their genome, a portion of the region E4 of an adenovirus genome carrying the reading phase ORF6 under the control of a functional promoter.

Abstract: This invention is directed to methods for stereospecifically preparing [(1-optionally substituted aryl)- or (1-optionally substituted heteroaryl)]-2-substituted ethyl-2-amines, having chirality at the 2-position, and to intermediates to the substituted ethyl-2-amines.

Abstract: A phospholipidic composition provides resistance against rancidity and the development of undesirable odors. The composition includes at least one phospholipid and a stabilizer. The stabilizer is ground parts and/or an extract of a grain. The composition is prepared by simple and reliable methods of production.

Abstract: This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.

Abstract: Biocompatible microspheres containing one or more active principals, a biodegradable and biocompatible polymer and a surface-active agent which is also biodegradable and biocompatible, contain less than 10 ppm of heavy metals. These microspheres are prepared by providing a solution of the polymer and of the active principal in a water-immiscible solvent which is more volatile than water and mixing with an aqueous solution of the surface-active agent, followed by evaporation of the solvent.

Abstract: Yeast strains expressing human genes coding regulating cytochrome P450 expression, a method for making same and applications thereof are described.

Abstract: A .beta.-phenylisoserine derivative of general formula (I): ##STR1## in the form of a salt or an ester, in which Ar represent an aryl radical, R represents a phenyl or naphthyl or a O--R.sub.1 radical and G.sub.1 represents --CH.sub.2 --Ph radical; and a method of using the same for making taxane derivatives.

Abstract: Cationic lipids of general formula (I), wherein m is an integer from 2 to 6 inclusive; n is an integer from 1 to 9 inclusive, preferably 1-5, where, when n is 2-9, a single R grouping other than hydrogen is present in the general formula, and m has variable or identical values within the groupings (a) or --(CH.sub.2).sub.m ; R is a hydrogen atom or a radical of general formula (II), wherein X or X.sup.1, which are the same or different, are an oxygen atom, a methylene grouping --(CH.sub.2).sub.q -- where q is 0, 1, 2 or 3, or an amino grouping --NH-- or NR.sup.1 --, where R is a C.sub.1-4 alkyl grouping; Y and Y.sup.1, which are the same or different, are a hydrogen atom or an optionally substituted C.sub.1-4 alkyl radical, and p is 0-5; and R.sub.6 is a cholesterol derivative or an alkylamino grouping --NR.sub.1 R.sub.2, where R.sub.1 and R.sub.2 are, independently of each other, a straight or branched, saturated or unsaturated C.sub.12-22 aliphatic radical.

Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: A compound of the formula ##STR1## in which Ra represents an -alk-COOalk' radical, a --CH.sub.2 --PO(Oalk).sub.2 radical, a --CH.dbd.CH--COOalk' radical or a phenyl radical substituted with an alkoxycarbonyl radical.

Abstract: This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

Abstract: An inhaler for inhaling pulverulent medicament from within a capsule comprises a chamber 24 within which the capsule is free to rotate while having its longitudinal axis in the median plane of the chamber and thus generally parallel to the front and rear walls 30 and 31 of the chamber, by virtue of the fact that the spacing between said front and rear walls is less than the axial length of the capsule but just greater than the diameter of the capsule. The device includes pins 21 serving as opening means to pierce the ends of the capsule while it is seated in a recess 25, whereupon the retraction of the pins 21 allows the capsule to be entrained into swirling airflow in the chamber 24 during inhalation of air through air inlets 26 and out through a mouthpiece nozzle 27.

Abstract: A sale unit for the parenteral application of liquid pharmaceutical products by the user is described, whereby the unit comprises at least one cannula, a device to emit a given liquid amount of the pharmaceutical product in single doses, as well as at least one vessel filled with the pharmaceutical product, the vessel being arranged within the device and emptied in single doses by means of the device, and whereby each single dose corresponds to the given liquid amount of the pharmaceutical product.

Abstract: The invention is directed to a device (V) for the output of a liquid (2) in partitioned amounts (2') from a store room (3), preferably in form of a cartridge (K), over an output mouth piece (4), preferably in form of an injection needle (5), and has the object the application of exactly reproducible amounts from a reserve amount and its safe application. This is obtained by an intermediate reservoir (17) taking up the partitioned amount (2') from the store room (3), whereby for the intermediate reservoir (17) an output piston (19) is provided with a penetration canal (18) to fill the intermediate reservoir (17).

Abstract: A compound of formula (II): ##STR1## in which R is a hydrogen atom or a carboxy, alkoxycarbonyl, --CO--NR.sub.4 R.sub.5, --PO.sub.3 H.sub.2 or --CH.sub.2 OH radical, and R.sub.1 is an -alk-NH.sub.2, -alk-NH--CO--R.sub.3, -alk-COOR.sub.4, -alk-CO--NR.sub.5 R.sub.6 or --CO--NH--R.sub.7 radical. The compounds of formula (II) can be used to prepare compounds of formula (I): ##STR2## in which R and R.sub.1 have the same meanings as above. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, also known as the quisqualate receptor. The compounds of formula (I) are also non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor and more specifically are ligands for NMDA receptor glycine modulator sites.

Abstract: This invention is directed to compounds of formula I: ##STR1## wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase.